APP - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
FEN1	flap structure-specific endonuclease 1	POLB-Dependent Long Patch Base Excision Repair Early Phase of HIV Life Cycle Removal of the Flap Intermediate from the C-strand PCNA-Dependent Long Patch Base Excision Repair HDR through MMEJ (alt-NHEJ) Removal of the Flap Intermediate	Iron Ferrous gluconate Ferrous succinate Ferrous ascorbate Ferrous fumarate Ferrous glycine sulfate
FERMT2	FERM domain containing kindlin 2	Cell-extracellular matrix interactions RAC1 GTPase cycle RAC3 GTPase cycle
FERMT3	FERM domain containing kindlin 3	Platelet degranulation		Leukocyte adhesion deficiency (LAD), including the following four diseases: Leukocyte adhesion deficiency (I); Leukocyte adhesion deficiency (II); Leukocyte adhesion deficiency (III); LAD with Rac2 deficiency
FES	FES proto-oncogene, tyrosine kinase	Signaling by SCF-KIT Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling	Fostamatinib
FEZF2	FEZ family zinc finger 2
FGA	fibrinogen alpha chain	Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants Amyloid fiber formation	Alteplase Reteplase Anistreplase Tenecteplase Sucralfate Zinc Alfimeprase Ancrod EP-2104R Lanoteplase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Familial amyloidosis Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia
FGB	fibrinogen beta chain	Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants	Sucralfate Alfimeprase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex	Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia
FGF12	fibroblast growth factor 12	Phase 0 - rapid depolarisation
FGF13	fibroblast growth factor 13	Phase 0 - rapid depolarisation
FGF16	fibroblast growth factor 16	PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR3c ligand binding and activation FGFR2c ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
FGFBP2	fibroblast growth factor binding protein 2	FGFR2b ligand binding and activation
FGFR2	fibroblast growth factor receptor 2	Signaling by FGFR2 amplification mutants Activated point mutants of FGFR2 Signaling by FGFR2 in disease Signaling by FGFR2 IIIa TM Signaling by FGFR2 fusions	Palifermin Heparin Sucrosofate 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Gastric cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
FGG	fibrinogen gamma chain	Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants	Alteplase Sucralfate Thrombin Human thrombin Thrombin alfa	Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia
FHIP2B	FHF complex subunit HOOK interacting protein 2B
FHL1	four and a half LIM domains 1			X-linked myopathy with postural muscle atrophy (XMPMA) Scapuloperoneal myopathy (SPM) Reducing body myopathy (RBM) Emery-Dreifuss muscular dystrophy
FHL2	four and a half LIM domains 2	PPARA activates gene expression
FIBP	FGF1 intracellular binding protein
FIG4	FIG4 phosphoinositide 5-phosphatase	Synthesis of PIPs at the Golgi membrane Synthesis of PIPs at the Golgi membrane Synthesis of PIPs at the early endosome membrane Synthesis of PIPs at the early endosome membrane Synthesis of PIPs at the late endosome membrane Synthesis of PIPs at the late endosome membrane		Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
FILIP1	filamin A interacting protein 1	RHOD GTPase cycle
FIP1L1	factor interacting with PAPOLA and CPSF1	Transport of Mature mRNA Derived from an Intronless Transcript mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs Signaling by cytosolic PDGFRA and PDGFRB fusion proteins

Search Results for: APP